Compare Kymera Therapeutics Inc. Common Stock (KYMR) vs Nasdaq Inc (NDAQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kymera Therapeutics Inc. Common Stock vs Nasdaq Inc — how do they compare? Kymera Therapeutics Inc. Common Stock trades at $106.9 (market cap $8.87B), while Nasdaq Inc trades at $91.96 (market cap $52.25B). The key difference: Nasdaq Inc is far larger — about 5.9× Kymera Therapeutics Inc. Common Stock's market cap, and Nasdaq Inc pays a 1.24% dividend while Kymera Therapeutics Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kymera Therapeutics Inc. Common Stock for 0 Days and Nasdaq Inc for 126 Days on average.
| KYMR | NDAQ | |
|---|---|---|
Market Cap | $8.87B | $52.25B |
Volume | 779,107 | 2,420,834 |
Sector | Health | Financials |
52-Week High | $127.31 | $100.98 |
52-Week Low | $55.80 | $76.85 |
Typical Hold Time | 0 Days | 126 Days |
Enterprise Value | $8.26B | $58.71B |
Dividend Yield | — | 1.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
Nasdaq (NDAQ) trades at $91.96, down 2.47% on the day, with a bullish technical outlook supported by moving averages. The company shows strong fundamentals with 2025 revenue of $8.26B and net income of $1.79B, achieving a 21.64% profit margin. Recent earnings beats and analyst consensus of $110.43 price target reflect confidence in growth driven by financial technology and AI initiatives.
NDAQ presents a compelling investment case with solid profitability and strategic positioning in market infrastructure. Key risks include market volatility sensitivity and debt levels, but strong cash flow and institutional support provide stability. The stock offers upside potential aligned with analyst targets, supported by recurring revenue growth and technology adoption.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Kymera Therapeutics Inc. Common Stock
Kymera Therapeutics, Inc. is a biopharmaceutical company developing small-molecule medicines based on targeted protein degradation, using its Pegasus platform to direct the body's natural protein-disposal system against disease-causing proteins.
Read more on KYMR →About Nasdaq Inc
Founded in 1971, Nasdaq is primarily known for its equity exchange, but in addition to its market-services business (about 35% of sales), the company sells and distributes market data as well as offers Nasdaq-branded indexes to asset managers and investors through its information-services segment (30%). Nasdaq's corporate-services business (20%) offers listing services and related investor relations products to publicly traded companies and through the company's market technology group (15%), Nasdaq facilitates the exchange operations of other exchanges throughout the world and provides financial compliance services.
Read more on NDAQ →
